Cristian Massacesi

Title: Cristian Massacesi: Innovator in Phosphatidylinositol 3-Kinase Inhibitors

Introduction

Cristian Massacesi is a notable inventor based in Neuilly-sur-Seine, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of dosage regimens for phosphatidylinositol 3-kinase (PI3K) inhibitors. With a total of 4 patents to his name, Massacesi's work is pivotal in the treatment of proliferative diseases.

Latest Patents

Massacesi's latest patents include innovative methods for treating or preventing proliferative diseases through the use of alpha-isoform selective PI3K inhibitors. One of his notable inventions outlines a dosage regimen that involves orally administering a therapeutically effective amount of a specific compound for at least two five-consecutive day cycles, with a break of two to three days between cycles. This regimen is designed to enhance the efficacy of the treatment for conditions such as cancer. Another patent focuses on a dosage regimen specifically for PI3K inhibitors, emphasizing the importance of tailored treatment plans for patients suffering from proliferative diseases.

Career Highlights

Throughout his career, Cristian Massacesi has worked with prominent companies in the pharmaceutical industry, including Novartis AG. His expertise in the field has allowed him to develop groundbreaking treatments that address critical health challenges.

Collaborations

Massacesi has collaborated with esteemed colleagues such as Samit Hirawat and Emmanuelle Di Tomaso. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Cristian Massacesi's contributions to the field of pharmaceuticals, particularly in the area of PI3K inhibitors, highlight his role as an influential inventor. His innovative approaches to treatment regimens are paving the way for improved patient outcomes in the fight against proliferative diseases.